United Imaging Healthcare Acquires Stake in Apactron for High-End Particle Therapy Technology
Shanghai-based United Imaging Healthcare (UIH, SHA: 688271) has announced an investment of RMB 45 million...
Cancer
Sequanta Technologies Partners with DarkJade Sciences to Establish Organoid Bank and Glioma Project
Sequanta Technologies, a leading multi-omics research and clinical service provider based in Shanghai, has announced...
Nanjing Leads Biolabs Receives FDA IND Approval for LBL-033 Phase I/II Clinical Trial
China-based Nanjing Leads Biolabs Co., Ltd has revealed that it has received Investigational New Drug...
TG ImmunoPharma Receives FDA Approval for Phase I Clinical Study of TGI-6 Bispecific Antibody
China-based TG ImmunoPharma Co., Ltd has announced that it has received approval from the US...
Aosaikang Pharmaceutical’s ASKB589 Shows Promising Results in Solid Tumor Treatment Study
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed the latest results from a Phase...
Jiangsu Hengrui Medicine Cancels Licensing Agreement with Mabworks Citing Market Changes
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced its decision to cancel a...
BeiGene to Showcase Brukinsa Data at ICML, Highlighting Efficacy in Relapsed Follicular Lymphoma
China-based biopharmaceutical company BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that it will...
Fosun Pharma Initiates Phase II Study of HLX26 and Serplulimab Combo for Metastatic CRC
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of...
Takeda and HutchMed’s Elunate Study Results Published in The Lancet
Takeda (TYO: 4502) and HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) have announced that the...
CStone’s Sugemalimab Shows Promising Survival Rates in Stage IV NSCLC Treatment
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the prestigious journal Nature Cancer has published...
Jiangxi Jemincare’s JYB1907 Receives NMPA Approval for Clinical Study in Solid Tumors
China-based Jiangxi Jemincare Group has announced that it has received approval from the China National...
Cytocraft Biotech’s SDT-T002 Cell Therapy Approved for Advanced Liver Cancer by NMPA
China-based Cytocraft Biotech Development has announced that its cell therapy, SDT-T002, has obtained clinical trial...
AbbVie Inc. Files Lawsuit Against BeiGene Over BTK Inhibitor Brukinsa
US-based AbbVie Inc., (NYSE: ABBV), the company behind the first-in-class Bruton’s tyrosine kinase (BTK) inhibitor...
Dartsbio Pharmaceuticals and SIMM Receive NMPA Approval for ADC DS001 Clinical Trial
Guangdong-based antibody drug developer Dartsbio Pharmaceuticals has partnered with the Shanghai Institute of Materia Medica...
Ascletis Pharma Inc. Ceases Promotion of Hepatitis C Products and Halts Development of ASC06 and ASC09
China-based Ascletis Pharma Inc., (HKG: 1672) has announced significant business adjustments, including the decision to...
Hansoh Pharmaceutical Gets NMPA Approval for HIF-2α Inhibitor HS-10516 Clinical Study
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that it has received approval...
Convalife Pharmaceuticals Gets NMPA Approval for Generic Neratinib Clinical Study
Shanghai-based Convalife Pharmaceuticals has announced that it has received approval from the National Medical Products...
Mass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research
Top-tier US medical institution Mass General Brigham Incorporated (MGB) has signed a sponsored research agreement...
Dizal Pharmaceutical’s Sunvozertinib Gets EU Approval for Global Phase III Study
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced receiving the green light from EU...
CSPC Pharmaceutical Gets NMPA Approval for ATM Inhibitor SYH2051 Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...